Clinical Application of Mass Spectrometry‐Based Proteomics in Lung Cancer Early Diagnosis

Gasparri, Roberto; Sedda, Giulia; Noberini, Roberta; Bonaldi, Tiziana; Spaggiari, Lorenzo

doi:10.1002/prca.201900138

Cited by 17 publications

(15 citation statements)

References 101 publications

(79 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In line with previous research, [45, 62–68] we find a number of proteins that demonstrate p‐values below 0.0005 (Table S4). However, the purpose of this study is not the search for specific biomarking candidates; instead, we wish to evaluate whether lung cancer results in a pattern of changes in protein concentrations responsible for its IR signature.…”

Section: Resultssupporting

confidence: 92%

Molecular Origin of Blood‐Based Infrared Spectroscopic Fingerprints**

et al. 2021

View full text Add to dashboard Cite

Infrared spectroscopyo fl iquid biopsies is at imeand cost-effective approach that may advance biomedical diagnostics.H owever,t he molecular nature of disease-related changes of infrared molecular fingerprints (IMFs) remains poorly understood, impeding the methodsa pplicability.H ere we probe 148 human blood sera and reveal the origin of the variations in their IMFs.Tothat end, we supplemented infrared spectroscopyw ith biochemical fractionation and proteomic profiling,p roviding molecular information about serum composition. Using lung cancer as an example of am edical condition, we demonstrate that the disease-related differences in IMFs are dominated by contributions from twelve highly abundant proteins-that, if used as ap attern, may be instrumental for detecting malignancy.T ying proteomic to spectral information and machine learning advances our understanding of the infrared spectra of liquid biopsies, af ramework that could be applied to probing of any disease.

show abstract

Section: Resultssupporting

confidence: 92%

Molecular Origin of Blood‐Based Infrared Spectroscopic Fingerprints**

et al. 2021

View full text Add to dashboard Cite

show abstract

“…In line with previous research, [45,[62][63][64][65][66][67][68] we find anumber of proteins that demonstrate p-values below 0.0005 (Table S4). However,t he purpose of this study is not the search for specific biomarking candidates;i nstead, we wish to evaluate whether lung cancer results in apattern of changes in protein concentrations responsible for its IR signature.…”

Section: Combining Ms-based Proteomics and Ir Fingerprinting Reveals Lung Cancer-related Molecular Changes In Blood Serumsupporting

confidence: 92%

“…Thus, we turned to the proteomic measurements of the same sample set -aiming for the identification of individual proteins responsible for the observed changes in the IMFs. In line with previous research (56)(57)(58)(59)(60), we find a number of proteins that demonstrate p-values below 0.0005 (SI Appendix Table S4). However, the purpose of this study is not the search for specific biomarking candidates; instead, we wish to evaluate whether lung cancer results in a pattern of changes in protein concentrations responsible for its IR signature.…”

Section: Combining Ms-based Proteomics and Ir Fingerprinting Reveals ...supporting

confidence: 91%

Molecular Origin of Blood‐Based Infrared Spectroscopic Fingerprints**

et al. 2021

View full text Add to dashboard Cite

Infrared spectroscopy of liquid biopsies is a timeand cost-effective approach that may advance biomedical diagnostics. However, the molecular nature of disease-related changes of infrared molecular fingerprints (IMFs) remains poorly understood, impeding the methods applicability. Here we probe 148 human blood sera and reveal the origin of the variations in their IMFs. To that end, we supplemented infrared spectroscopy with biochemical fractionation and proteomic profiling, providing molecular information about serum composition. Using lung cancer as an example of a medical condition, we demonstrate that the disease-related differences in IMFs are dominated by contributions from twelve highly abundant proteins-that, if used as a pattern, may be instrumental for detecting malignancy. Tying proteomic to spectral information and machine learning advances our understanding of the infrared spectra of liquid biopsies, a framework that could be applied to probing of any disease.

show abstract

“…Research focusing on blood serum/plasma proteome profiling of cancer patients using mass spectrometry is ongoing. Laryngeal squamous cell cancer (LSCC) is one of the aggressive cancers, which makes it a good model for studying the metastasis mechanisms [ 2 , 3 , 4 ]. Earlier, we uncovered the differences in the blood serum proteome of LSCC patients and healthy volunteers, as well as the correlation between several functionally different proteins (including actin-binding protein CAP1 (adenylyl cyclase-associated protein 1)) [ 4 ] and metastases of LSCC.…”

Section: Introductionmentioning

confidence: 99%

Circulating Actin-Binding Proteins in Laryngeal Cancer: Its Relationship with Circulating Tumor Cells and Cells of the Immune System

et al. 2021

View full text Add to dashboard Cite

We previously exposed the role of actin-binding proteins (ABPs) in cancer development and progression. In this paper, we studied the relationship between circulating ABPs and the number of ABP-expressing leukocytes and circulating tumor cells (CTCs) in patients with highly aggressive laryngeal squamous cell carcinoma (LSCC). The levels of cofilin (CFL1), profilin (PFN1), ezrin (EZR), fascin (FSCN1), and adenylate cyclase-associated protein 1 (CAP1) were determined using enzyme immunoassay. The ABP expression by the cellular pools was analyzed by flow cytometry. The highest levels of FSCN1 and EZR were found in the blood serum of LSCC patients. There was a difference in ABP expression between the pools of leukocytes and CTCs. Leukocytes were mainly represented by CAP1+ and FSCN1+ pools, and CTCs contained CAP1+, FSCN1+, and EZR+ cells. The serum FSCN1 level correlated with the number of FSCN1-containing and CFL1-containing leukocytes. Thus, the level of circulating EZR is likely related to its expression in CTCs. The levels of CFL1 and PFN1 are likely to be supported by the expression of these proteins by leukocytes. Both CTCs and leukocytes can be a source of FSCN1 and CAP1 in blood serum. The results suggest that serum proteins can be produced by various cells, thus indicating both cancer development and the response of the immune system to this process.

show abstract

Clinical Application of Mass Spectrometry‐Based Proteomics in Lung Cancer Early Diagnosis

Cited by 17 publications

References 101 publications

Molecular Origin of Blood‐Based Infrared Spectroscopic Fingerprints**

Molecular Origin of Blood‐Based Infrared Spectroscopic Fingerprints**

Molecular Origin of Blood‐Based Infrared Spectroscopic Fingerprints**

Circulating Actin-Binding Proteins in Laryngeal Cancer: Its Relationship with Circulating Tumor Cells and Cells of the Immune System

Contact Info

Product

Resources

About